152 related articles for article (PubMed ID: 8157036)
21. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
Leitersdorf E; Eisenberg S; Eliav O; Friedlander Y; Berkman N; Dann EJ; Landsberger D; Sehayek E; Meiner V; Wurm M
Circulation; 1993 Apr; 87(4 Suppl):III35-44. PubMed ID: 8462179
[TBL] [Abstract][Full Text] [Related]
22. Clinical efficacy of fluvastatin for hyperlipidemia in Japanese patients.
Teramoto T; Goto Y; Kurokawa K; Nakamura H; Yoshida S; Saito Y; Nakaya N; Itakura H; Takaku F; Yamada N
Am J Cardiol; 1995 Jul; 76(2):33A-36A. PubMed ID: 7604794
[TBL] [Abstract][Full Text] [Related]
23. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of fluvastatin, a new HMG CoA reductase inhibitor, in elderly hypercholesterolaemic women.
Baggio G; De Candia O; Forte PL; Mello F; Andriolli A; Donazzan S; Valerio G; Milani M; Crepaldi G
Drugs; 1994; 47 Suppl 2():59-63. PubMed ID: 7517835
[TBL] [Abstract][Full Text] [Related]
25. [Fluvastatin in the treatment of hyperlipoproteinemia, initial experience].
Ceska R
Vnitr Lek; 1996 Aug; 42(8):533-6. PubMed ID: 8967021
[TBL] [Abstract][Full Text] [Related]
26. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
Bard JM; Ose L; Hagen E; Duriez P; Pfister P; Fruchart JC; Dallongeville J
Am J Cardiol; 1995 Jul; 76(2):65A-70A. PubMed ID: 7604802
[TBL] [Abstract][Full Text] [Related]
27. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
Holdaas H; Hartmann A; Stenstrøm J; Dahl KJ; Borge M; Pfister P
Am J Cardiol; 1995 Jul; 76(2):102A-106A. PubMed ID: 7604781
[TBL] [Abstract][Full Text] [Related]
28. Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia.
Tomlinson B; Mak TW; Tsui JY; Woo J; Shek CC; Critchley JA; Masarei JR
Am J Cardiol; 1995 Jul; 76(2):136A-139A. PubMed ID: 7604789
[TBL] [Abstract][Full Text] [Related]
29. [The efficacy, safety and tolerance of fluvastatin sodium 40 mg in patients with hyperlipidemia type IIA].
Fanghänel Salmón G; Salgado Loza JL; Sánchez Reyes L; Padilla Retana JA; Espinosa Campos J
Arch Inst Cardiol Mex; 1996; 66(2):151-6. PubMed ID: 8768633
[TBL] [Abstract][Full Text] [Related]
30. Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
Sigurdsson G; Haraldsdottir SO; Melberg TH; Tikkanen MJ; Miettinen TE; Kristianson KJ
Acta Cardiol; 1998; 53(1):7-14. PubMed ID: 9638964
[TBL] [Abstract][Full Text] [Related]
31. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.
Derosa G; Mugellini A; Ciccarelli L; Fogari R
Clin Ther; 2003 Apr; 25(4):1107-22. PubMed ID: 12809960
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial.
Zavoral JH; Haggerty BJ; Winick AG; Bergmann SD
Am J Cardiol; 1995 Jul; 76(2):37A-40A. PubMed ID: 7604795
[TBL] [Abstract][Full Text] [Related]
33. Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk. An analysis of a clinical trial database.
Peters TK; Muratti EN; Mehra M
Am J Med; 1994 Jun; 96(6A):79S-83S. PubMed ID: 8017471
[TBL] [Abstract][Full Text] [Related]
34. Open-label study to assess the efficacy, safety, and tolerability of fluvastatin versus bezafibrate for hypercholesterolemia.
Fanghänel G; Espinosa J; Olivares D; Sánchez L; Morales M; Martínez L; Macías G; Valdés E; Hernández G
Am J Cardiol; 1995 Jul; 76(2):57A-61A. PubMed ID: 7604800
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia: preliminary report.
Knopp RH; Frolich JJ
Am J Cardiol; 1994 May; 73(14):39D-41D. PubMed ID: 8198023
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of fluvastatin in women with primary hypercholesterolaemia.
Peters TK; Muratti EN; Mehra M
Drugs; 1994; 47 Suppl 2():64-72. PubMed ID: 7517836
[TBL] [Abstract][Full Text] [Related]
37. Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia.
Li PK; Mak TW; Chan TH; Wang A; Lam CW; Lai KN
Transplantation; 1995 Oct; 60(7):652-6. PubMed ID: 7570971
[TBL] [Abstract][Full Text] [Related]
38. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage.
Smit JW; Jansen GH; de Bruin TW; Erkelens DW
Am J Cardiol; 1995 Jul; 76(2):126A-128A. PubMed ID: 7604787
[TBL] [Abstract][Full Text] [Related]
39. Fluvastatin with and without niacin for hypercholesterolemia.
Jacobson TA; Chin MM; Fromell GJ; Jokubaitis LA; Amorosa LF
Am J Cardiol; 1994 Jul; 74(2):149-54. PubMed ID: 8023779
[TBL] [Abstract][Full Text] [Related]
40. Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group.
Dallongeville J; Fruchart JC; Pfister P; Bard JM
J Intern Med Suppl; 1994; 736():95-101. PubMed ID: 7986315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
